GBS Inc. (GBS): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
GBS Stock Price Chart Interactive Chart >
GBS Price/Volume Stats
| Current price | $4.45 | 52-week high | $14.24 |
| Prev. close | $4.32 | 52-week low | $2.44 |
| Day low | $4.33 | Volume | 455,200 |
| Day high | $4.75 | Avg. volume | 492,491 |
| 50-day MA | $3.83 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 55.10M |
GBS Inc. (GBS) Company Bio
GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest GBS News From Around the Web
Below are the latest news stories about GBS Inc that investors may wish to consider to help them evaluate GBS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're at the midpoint of the week now and we're still going strong with a look at the biggest pre-market stock movers for Wednesday. |
We Think GBS (NASDAQ:GBS) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investors! |
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring SurveyGlobal results show 90% of patients are in favor of a saliva-based glucose testNEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced survey results from more than 300 patients globally as part of its development and go-to-market strategy. As GBS is advancing to clinical trials of its saliva glucose biosensor, it conducte |
Will GBS (NASDAQ:GBS) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
GBS Price Returns
| 1-mo | 42.17% |
| 3-mo | -32.16% |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.86% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...